北京若生智能科技有限公司
Drug Database
ET

etanercept

✓ Approved

Harvest Moon Pharmaceuticals · TNF · 重组蛋白

什么是 etanercept？

etanercept 是一种重组蛋白，由Harvest Moon Pharmaceuticals研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intraarticular Injection、Intravenous (IV)、Subcutaneous Injection。

药物档案

公司Harvest Moon Pharmaceuticals
药物类别重组蛋白
分子靶点TNF
给药途径Injectable (Others), Intraarticular Injection, Intravenous (IV), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Harvest Moon Pharmaceuticals

作用机制

分子靶点

etanercept 作用于 1 个分子靶点：

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

etanercept 针对 5 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Musculoskeletal and connective tissue disordersAnkylosing spondylitisPreclinical
Skin and subcutaneous tissue disordersPsoriasisPreclinical
Musculoskeletal and connective tissue disordersPsoriatic arthropathyPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

相关研究文献

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-09-10

SOX30 Facilitates Triple-Negative Breast Cancer Metastasis via TNFR2-NF-κB Signaling and Tumor Microenvironment Remodeling.

Gao Pingping P, Sun Na N, Yang Ning N, Zhao Tingting T et al.

Triple-negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2-mediated downstream NF-κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor-associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2-NF-κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small-molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti-metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30-TNFR2-NF-κB-CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti-metastatic strategies in TNBC.

PMID 42717500
阅读全文 →
PubMedFrontiers in pharmacology2026-09-10

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.

Ameer Omar Z OZ, Temsah Reem R, Alsouss Yara O YO, Al-Amoudi Raghad R et al.

Ankylosing spondylitis (AS) is a prototypical axial spondyloarthritis (axSpA) defined by chronic inflammatory back pain, progressive spinal stiffness, and frequent extra-articular manifestations such as acute anterior uveitis (21%-33%), inflammatory bowel disease (5%-10%), and psoriasis (4%-13%). Management has shifted from non-steroidal anti-inflammatory drugs (NSAIDs) to highly targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). This comprehensive review focuses on the current evidence for biologic and targeted synthetic therapeutics in the management of AS, emphasizing mechanisms of action, regulatory approvals, dosing regimens, and clinical efficacy. Three major therapeutic classes are identified: two biologic DMARD classes, comprising tumor necrosis factor-alpha (TNF-α) inhibitors and interleukin-17 (IL-17) inhibitors, and the targeted synthetic DMARDs, namely, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors. TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies; psoriasis favors IL-17 inhibitors), safety profile, route of administration, and sequencing after non-steroidal anti-inflammatory drug failure. Understanding these pharmacological distinctions enables personalized therapeutic decisions based on the specific molecular pathology and risk profile of the individual patient.

PMID 42719014
阅读全文 →
PubMedBlood cell therapy2026-09-08

Etanercept in Steroid-Refractory Acute Graft Versus Host Disease: Clinical Response, Toxicity, and Long-Term Outcomes.

Chichra Akanksha A, Punatar Sachin S, Gokarn Anant A, Mirgh Sumeet S et al.

Steroid refractory acute graft versus host disease (SR-aGVHD) is seen in 30%-40% of patients undergoing allogeneic hematopoietic stem cell transplant (allo HSCT). We report our experience with etanercept (ETA) as a first-line treatment for SR-aGVHD during a period when ruxolitinib was not available in India. We retrospectively analysed 43 allo HSCT patients from 2010 to 2019 who received ETA for SR-aGVHD. The primary objective was to assess the overall response rate with etanercept. Secondary objectives included overall survival (OS), organ specific responses, causes of mortality and identification of factors associated with survival and see its utility in the current ruxolitinib era. The response rates (overall response rate [ORR] - complete response [CR] + very good partial response [VGPR] + partial response [PR]) at Day 28 was 69%. The organ-specific ORR was 70% (lower gut), 67% (skin), and 50% (liver). The median OS of responders at Day 28 from ETA start was 6.8 months versus 2.8 months in non-responders (p=0.0008). Patients in whom a reduction in the systemic steroid dose of ≥ 30% by Day 28 from ETA start was possible had a significantly longer median OS (9.5 months versus 3.5 months; p=0.0001). In multivariate analysis, steroid dose reduction of ≥ 30% by Day 28 of the start of ETA was a significant factor for survival (p=0.015). The cause of death in the majority was infection (90%). ETA, used as a second-line agent, has shown an acceptable ORR for SR-aGVHD in our cohort. Despite the good response rates, the group had a high transplantation-related mortality. Infections were the major cause of mortality, and early tapering of systemic steroids may be the key to improving outcomes. In the current ruxolitinib era, etanercept may hold a place in patients where ruxolitinib has failed or is not feasible.

PMID 42707435
阅读全文 →
PubMedThe Journal of dermatological treatment2026-09-07

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update.

Fatani Mohammed Ibrahim MI, Binamer Yousef Y, Alessa Dana D, Almudaiheem Hajer Y HY et al.

Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 5.3% of the population in the Kingdom of Saudi Arabia (KSA). Thus, we aim to develop updated evidence-based clinical practice guidelines for the management of adults and pediatric patients with moderate-to-severe plaque psoriasis in the KSA. These guidelines followed the "Grading of Recommendations, Assessment, Development, and Evaluation" (GRADE) methodology. We conducted a systematic literature review of PubMed, EMBASE, and the Cochrane Library for high-quality evidence published between 2020 and 2026. The panel developed 31 PICO questions that address key treatment considerations for moderate-to-severe psoriasis. We established 27 evidence-based recommendations and 4 good-practice statements addressing key aspects of moderate-to-severe psoriasis management. These guidelines strongly recommend adopting the Psoriasis Area and Severity Index (PASI) 90 as the primary treatment goal over PASI 75. For adult patients, the guidelines recommend biologic therapies, including interleukin (IL)-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, and tumor necrosis factor (TNF)-α inhibitors, for better disease control. For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options. These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients.

PMID 42704198
阅读全文 →
PubMedFrontiers in digital health2026-09-03

The Sicilian Web plAtform for Rheumatology Network: complete regional implementation and first-year real-world drug utilisation.

Corrao Salvatore S, Provenzano Giuseppe G, Bentivegna Mario M, Oteri Alessandro A et al.

In the evolving landscape of chronic disease management, digital platforms have emerged as tools to support care coordination, standardised prescribing and clinical governance. Building on the precedent of the HCV Sicily Network, the Sicilian Web plAtform for Rheumatology Network (SWaNetwork) was developed to provide a regional digital infrastructure for standardised rheumatologic prescribing, conceived as the foundation of a continuously evolving regional real-world data ecosystem. This report describes the complete regional implementation of the SWaNetwork across all authorised Sicilian rheumatology prescribing centres and presents the first-year real-world prescribing data generated by the platform. SWaNetwork is a secure, web-based platform launched in October 2022, designed to manage the complete process of prescribing and dispensing rheumatologic therapies. Developed in collaboration with the CINECA Interuniversity Consortium, the system integrates data from 14 regional prescribing centres, providing real-time dashboards, automated alerts, and structured reports to support clinical governance. Descriptive analyses were performed using Stata 18. This is a descriptive implementation and drug-utilisation report; no comparator group or clinical-effectiveness outcomes were analysed. In its first year, all 14 authorised regional prescribing centres were fully onboarded and 71 healthcare professionals registered 8,243 patients, with a platform-defined follow-up completion rate of 98%. A total of 1,426 initial prescriptions and 40,025 follow-up prescriptions were recorded (41,451 prescriptions overall), predominantly involving biologics such as Adalimumab (33.4%) and Etanercept (24.3%). These findings describe the scale and drug-utilisation pattern generated during the first year of regional implementation. The SWaNetwork achieved complete regional implementation and generated a comprehensive first-year real-world prescribing dataset across Sicily. Rather than demonstrating clinical effectiveness, this foundational report describes a regional digital infrastructure for standardised prescribing governance, laying the foundation for a continuously evolving regional real-world data ecosystem, and provides the basis for future studies on treatment persistence, drug survival, switching, effectiveness, safety, healthcare utilisation and pharmacoeconomic outcomes.

PMID 42688897
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-31

Multi-Technique Integration Identifies O-GlcNAc Transferase in Fibroblast-Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis.

Xie Duoli D, Huang Jie J, Cao Chunhao C, Tang Zhenchao Z et al.

Rheumatoid arthritis (RA) progression is driven by the pathogenic transformation of stromal fibroblast-like synoviocytes (FLSs). Using artificial intelligence-guided analysis of a synovial single-cell transcriptomic dataset, we identify O-GlcNAc transferase (OGT) as a key regulator enriched in RA-FLSs. Gain- and loss-of-function studies demonstrate that OGT is necessary to drive aggressive FLS phenotypes and exacerbate experimental arthritis. Mechanistically, OGT-mediated O-GlcNAcylation stabilizes SAP130, promoting histone deacetylation at the BTG2 promoter. This facilitates the deposition of repressive histone methylation marks, leading to BTG2 epigenetic silencing and ultimately fueling FLS aggression. To translate this mechanistic insight, we develop an FLS-targeted proteolysis-targeting chimera (PROTAC) by conjugating the OGT inhibitor OSMI-1 to the AS1411 aptamer, which selectively binds surface nucleolin (NCL) overexpressed on pathogenic FLSs and, upon internalization, employs NCL as a molecular bridge to recruit the E3 ligase MDM2 for cell-selective OGT degradation. This PROTAC suppresses FLS pathogenicity, attenuates arthritis in mice, and demonstrates additive therapeutic benefit when combined with the TNF-α inhibitor etanercept. Collectively, our work establishes a translational paradigm that progresses from AI-driven target discovery and mechanistic elucidation to the rational design of a cell-type-specific degradation therapy, offering a strategy to overcome the stromal-driven therapeutic barrier in RA.

PMID 42671010
阅读全文 →

注册免费账户还可查看另外 8474 篇文献

免费注册查看全部文献 →

了解更多etanercept